WO2001013901A3 - Systeme d'administration pharmaceutique de vitamine c et vitamine e et utilisation d'une combinaison de ces vitamines permettant de prevenir ou de traiter des conditions provoquant un stress oxydatif - Google Patents

Systeme d'administration pharmaceutique de vitamine c et vitamine e et utilisation d'une combinaison de ces vitamines permettant de prevenir ou de traiter des conditions provoquant un stress oxydatif Download PDF

Info

Publication number
WO2001013901A3
WO2001013901A3 PCT/DK2000/000459 DK0000459W WO0113901A3 WO 2001013901 A3 WO2001013901 A3 WO 2001013901A3 DK 0000459 W DK0000459 W DK 0000459W WO 0113901 A3 WO0113901 A3 WO 0113901A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
delivery system
oxidative stress
pharmaceutical delivery
preventing
Prior art date
Application number
PCT/DK2000/000459
Other languages
English (en)
Other versions
WO2001013901A2 (fr
Inventor
Bent Hoejgaard
Henrik Enghusen Poulsen
Jukka Salonen
Original Assignee
Ferrosan As
Bent Hoejgaard
Henrik Enghusen Poulsen
Jukka Salonen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrosan As, Bent Hoejgaard, Henrik Enghusen Poulsen, Jukka Salonen filed Critical Ferrosan As
Priority to AU65589/00A priority Critical patent/AU6558900A/en
Priority to PL00356667A priority patent/PL356667A1/xx
Priority to EP00952964A priority patent/EP1210079A2/fr
Priority to JP2001518039A priority patent/JP2003507419A/ja
Priority to NZ517833A priority patent/NZ517833A/en
Publication of WO2001013901A2 publication Critical patent/WO2001013901A2/fr
Publication of WO2001013901A3 publication Critical patent/WO2001013901A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un système d'administration pharmaceutique qui comprend une préparation de vitamine C (acide ascorbique) à diffusion lente et une préparation à diffusion simple de vitamine E (tocophérol) qui s'est révélé efficace pour augmenter et stabiliser les concentrations de ces vitamines dans le plasma sanguin à un taux d'environ 2.2:1. La concentration permanente et le taux de ces antioxydants s'avèrent importants dans la prévention et le traitement du stress oxydatif lié aux troubles tels que l'artériosclérose, le diabète et les troubles dégénérescents neuronaux comme la maladie d'Alzheimer.
PCT/DK2000/000459 1999-08-20 2000-08-18 Systeme d'administration pharmaceutique de vitamine c et vitamine e et utilisation d'une combinaison de ces vitamines permettant de prevenir ou de traiter des conditions provoquant un stress oxydatif WO2001013901A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU65589/00A AU6558900A (en) 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
PL00356667A PL356667A1 (en) 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
EP00952964A EP1210079A2 (fr) 1999-08-20 2000-08-18 Systeme d'administration pharmaceutique de vitamine c et vitamine e et utilisation d'une combinaison de ces vitamines permettant de prevenir ou de traiter des conditions provoquant un stress oxydatif
JP2001518039A JP2003507419A (ja) 1999-08-20 2000-08-18 ビタミンｃとビタミンｅの医薬デリバリーシステムと酸化ストレスを含む症状の予防または治療へのビタミンｃとビタミンｅの組合せ使用
NZ517833A NZ517833A (en) 1999-08-20 2000-08-18 Oral delivery of antioxidants vitamin C and vitamin E combinations in slow- and plain-release formulations for treating oxidative stress

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901145 1999-08-20
DKPA199901145 1999-08-20

Publications (2)

Publication Number Publication Date
WO2001013901A2 WO2001013901A2 (fr) 2001-03-01
WO2001013901A3 true WO2001013901A3 (fr) 2001-09-07

Family

ID=8101522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000459 WO2001013901A2 (fr) 1999-08-20 2000-08-18 Systeme d'administration pharmaceutique de vitamine c et vitamine e et utilisation d'une combinaison de ces vitamines permettant de prevenir ou de traiter des conditions provoquant un stress oxydatif

Country Status (8)

Country Link
EP (1) EP1210079A2 (fr)
JP (1) JP2003507419A (fr)
AR (1) AR025343A1 (fr)
AU (1) AU6558900A (fr)
NZ (1) NZ517833A (fr)
PL (1) PL356667A1 (fr)
RU (1) RU2309733C2 (fr)
WO (1) WO2001013901A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078296A2 (fr) * 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tococotrienol et/ou derives de tocotrienol pour le traitement therapeutique ou prophylactique de troubles provoques par le glutamate et/ou le calcium
JP2005521707A (ja) * 2002-03-28 2005-07-21 オキシス インターナショナル， インコーポレイテッド 神経保護方法、組成物、およびそのスクリーニング法
KR20050086954A (ko) * 2003-01-17 2005-08-30 바이탈 헬스 사이언시즈 피티와이 리미티드 항증식성 화합물
EP1689381B1 (fr) * 2003-09-05 2010-02-24 Matthias Rath Composition pharmaceutique, comprenant notamment de la vitamine c, du magnesium et de l'extrait de the vert, destinee a retarder des maladies cardiovasculaires (proliferation des smc)
WO2011094814A1 (fr) 2010-02-05 2011-08-11 Phosphagenics Limited Vecteur comprenant du phosphate de tocophéryle non neutralisé
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
CN110662733A (zh) 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
WO2022059776A1 (fr) * 2020-09-17 2022-03-24 昭和電工株式会社 Activateur d'autophagie

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
EP0176772A1 (fr) * 1984-08-30 1986-04-09 RODISMA Pharmazeutische Produkte GmbH Procédé pour augmenter l'effet de retardement des vitamines C et E
JPH07227256A (ja) * 1993-12-24 1995-08-29 Takeda Chem Ind Ltd 経口液剤
WO1997000672A1 (fr) * 1995-06-23 1997-01-09 Defelice Stephen L Compose nutritionnel et/ou dietetique et son procede d'utilisation
EP0820703A1 (fr) * 1996-07-22 1998-01-28 Valpharma S.A. Compositions pour intégration nutritionelle comprenant des vitamines hydrosolubles à libération prolongée
US5897879A (en) * 1994-05-03 1999-04-27 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Sustained-release pharmaceutical system for the delivery of antioxidants
WO1999033448A1 (fr) * 1997-12-23 1999-07-08 Merck Patent Gmbh Comprime a liberation instantanee et prolongee d'un ou de plusieurs principes actifs
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
EP0176772A1 (fr) * 1984-08-30 1986-04-09 RODISMA Pharmazeutische Produkte GmbH Procédé pour augmenter l'effet de retardement des vitamines C et E
JPH07227256A (ja) * 1993-12-24 1995-08-29 Takeda Chem Ind Ltd 経口液剤
US5897879A (en) * 1994-05-03 1999-04-27 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Sustained-release pharmaceutical system for the delivery of antioxidants
WO1997000672A1 (fr) * 1995-06-23 1997-01-09 Defelice Stephen L Compose nutritionnel et/ou dietetique et son procede d'utilisation
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets
EP0820703A1 (fr) * 1996-07-22 1998-01-28 Valpharma S.A. Compositions pour intégration nutritionelle comprenant des vitamines hydrosolubles à libération prolongée
WO1999033448A1 (fr) * 1997-12-23 1999-07-08 Merck Patent Gmbh Comprime a liberation instantanee et prolongee d'un ou de plusieurs principes actifs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199543, Derwent World Patents Index; Class B05, AN 1995-331499, XP002901609 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound

Also Published As

Publication number Publication date
PL356667A1 (en) 2004-06-28
RU2309733C2 (ru) 2007-11-10
AU6558900A (en) 2001-03-19
EP1210079A2 (fr) 2002-06-05
WO2001013901A2 (fr) 2001-03-01
JP2003507419A (ja) 2003-02-25
NZ517833A (en) 2004-01-30
AR025343A1 (es) 2002-11-20
RU2002107015A (ru) 2003-11-10

Similar Documents

Publication Publication Date Title
JP3156787B2 (ja) スーパーオキシド消去剤
US5843411A (en) Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
KR100812596B1 (ko) 천연 유래 화합물을 포함하는 피부보호 조성물
EP0903143A3 (fr) Utilisation de la daidzéine pour la fabrication d'un médicament pour augmenter le niveau en cholestérol du type HDL
WO2001095899A3 (fr) Compositions pharmaceutiques renfermant des derives de cannabidiol
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
WO2001013901A3 (fr) Systeme d'administration pharmaceutique de vitamine c et vitamine e et utilisation d'une combinaison de ces vitamines permettant de prevenir ou de traiter des conditions provoquant un stress oxydatif
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
WO1994008551A3 (fr) Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume
EP0766960A4 (fr) Preparations a usage externe destinees au traitement de dermatoses
WO2001007064A1 (fr) Compositions antioxydantes synergiques servant a lutter contre les hemorroides et d'autres types d'inflammations ano-rectales
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
EP1351679B1 (fr) Methode et composition pour le traitement de neuropathies diabetiques
PL320687A1 (en) Use of incense for treating alzheimer disease
EP1393734A4 (fr) Medicaments pour les maladies intestinales
EP0910367B1 (fr) Utilisation de la vitamine e acetate
JP2003506116A (ja) ビタミンｅ及び必須脂肪酸を含む局所適用用組成物を噴霧分与するための装置
EP1393738A4 (fr) Traitement antidiabetique
IT1314199B1 (it) Composizioni contenenti sostanze ad attivita' adrenergica ed estrattivegetali per il trattamento del sovrappeso e obesita'
WO2002005801A3 (fr) Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
WO2003002125A3 (fr) Combinaison de sucres amines et cysteine ou de derives de cysteine
AU2001241315A1 (en) Use of a composition
EP1594456B1 (fr) Utilisation d'une composition contenant de l'oxyde de vitamine k1 ou un derive de ce dernier pour le traitement ou la prevention de lesions dermatologiques chez les mammiferes
Thornfeldt Cosmeceuticals: separating fact from voodoo science
US20040062779A1 (en) Dermatologic composition using ultra-fine/micronized 1-ascorbic acid and other antioxidant ingredients in a stabilized anhydrous vehicle

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000952964

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 517833

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 65589/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: RU

Ref document number: 2002 2002107015

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000952964

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 517833

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517833

Country of ref document: NZ